Hormonal
Lower levels of IGF-1 are associated with longer life span in mice, and this region overlaps with human longevity quantitative trait loci, suggesting a conserved mechanism where IGF-1 regulation influences longevity.
Research in mice suggests that lower IGF-1 levels may be associated with a longer life span. While human data is still correlational, this highlights the importance of metabolic health. Avoid excessive anabolic interventions that might spike IGF-1 unnecessarily, and focus on balanced nutrition and exercise.
Yuan and coworkers reported that across mouse inbred strains, lower IGF-1 levels are associated with longer life span. The overlap between longevity QTL and IGF-1 QTL suggests that this region may contain genes that could regulate longevity through the regulation of IGF-1 level.
Why this rating
Based on mouse QTL studies and human GWAS colocalization, not direct human intervention trials.
Source
The Search for Longevity and Healthy Aging Genes: Insights From Epidemiological Studies and Samples of Long-Lived Individuals
Joanne M. Murabito et al. · The Journals of Gerontology Series A · 2012
DOI 10.1093/gerona/gls089
More from this paper
- The ApoE E4 isoform is deleterious to longevity, while the E2 isoform is protective, with the E4 allele conferring up to an 8-15 fold increased risk for Alzheimer's disease and premature death from age-related conditions.Good
- FOXO3a variants are associated with increased human life span, with the minor allele conferring a higher odds of longevity (OR 2.75) in centenarians of Japanese descent, and this association has been replicated in diverse populations including German, Italian, Chinese, and Danish cohorts.Good
- Resveratrol improves insulin sensitivity in older adults with impaired glucose tolerance, supporting its potential as an intervention to delay aging based on its effects on the insulin/IGF-1 pathway.Limited
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →